All In Biotech

Drug Trial Radar · NCT06328712

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

May 30, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
ENCellIndustry
Sponsor type
Industry
First posted
Mar 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients with Charcot-Marie-Tooth Disease type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

Conditions

  • Charcot-Marie-Tooth Disease Type 1A

Interventions

  • EN001Drug

    * Cohort 1: EN001 Low dose administered intravenously (IV) 2 times at 4 week intervals. * Cohort 2: EN001 High dose administered intravenously (IV) 2 times at 4 week intervals.

  • EN001 PlaceboDrug

    EN001 Placebo administered intravenously (IV) 2 times at 4 week intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Phase 1b] Dose limiting toxicity (DLT) and adverse drug reactions related to discontinuation of investigational product administrationTime frame: Up to 8 weeks
  2. [Phase 2a] Change from baseline in the CMT Neuropathy Score (CMTNSv2) at Week 24.Time frame: at Week 24

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Dongguk University Gyeongju Hospital

    Gyeongju, South Korea · Recruiting

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.